Published in Oncotarget on November 24, 2015
Personalized Computational Models as Biomarkers. J Pers Med (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Cancer genome landscapes. Science (2013) 25.33
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med (2004) 5.67
The cancer biomarker problem. Nature (2008) 4.64
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol (2012) 4.47
Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med (2009) 4.19
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol (2014) 1.70
Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med (2009) 1.53
FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res (2014) 1.22
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol (2010) 1.18
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol (2007) 1.00
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Developing precision medicine in a global world. Clin Cancer Res (2014) 0.87
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 2.66
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell (2002) 2.54
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Metformin in cancer: translational challenges. J Mol Endocrinol (2012) 1.94
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res (2011) 1.79
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood (2005) 1.66
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol (2002) 1.64
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol (2008) 1.41
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst (2012) 1.37
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One (2009) 1.35
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Multifunctional role of Erk5 in multiple myeloma. Blood (2005) 1.22
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Neuregulins and cancer. Clin Cancer Res (2008) 1.21
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood (2008) 1.17
Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem (2003) 1.16
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol (2007) 1.16
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica (2008) 1.13
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res (2005) 1.09
Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst (2010) 1.07
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res (2010) 1.01
Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J (2002) 1.01
Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem (2006) 1.00
Multisite phosphorylation of Erk5 in mitosis. J Cell Sci (2010) 0.95
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica (2008) 0.95
Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells (2013) 0.95
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res (2008) 0.95
Deficient spindle assembly checkpoint in multiple myeloma. PLoS One (2011) 0.94
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol (2012) 0.93
Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer (2005) 0.93
Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther (2012) 0.92
A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. J Immunol Methods (2002) 0.92
Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem (2004) 0.91
Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol (2006) 0.91
Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Res Treat (2010) 0.90
Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal (2006) 0.90
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One (2009) 0.89
Erk5 is activated and acts as a survival factor in mitosis. Cell Signal (2007) 0.89
Do we have to change the way targeted drugs are developed? J Clin Oncol (2010) 0.88
The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev (2012) 0.88
Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal (2007) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal (2013) 0.87
Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res (2010) 0.86
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res (2015) 0.86
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant (2008) 0.85
Targeting HER receptors in cancer. Curr Pharm Des (2013) 0.85
Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res (2013) 0.85
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol (2008) 0.85
A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest (2004) 0.85
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer (2014) 0.83
Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol (2006) 0.83
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia (2013) 0.82
A modular approach to trim cellular targets in anticancer drug discovery. Bioorg Med Chem Lett (2011) 0.81
The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. Mol Biol Cell (2006) 0.81
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs (2012) 0.80
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer Metastasis Rev (2014) 0.79
Enhancement of antiproliferative activity by molecular simplification of catalpol. Bioorg Med Chem (2010) 0.78
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica (2011) 0.78
Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol (2010) 0.77
N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. Biochem J (2005) 0.77
Novel tyrosine kinase inhibitors in the treatment of cancer. Curr Drug Targets (2009) 0.77
Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. J Biochem (2005) 0.77
Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. Curr Cancer Drug Targets (2017) 0.76
Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. J Med Chem (2010) 0.76
Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains. J Biol Chem (2011) 0.75
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Mol Cancer Ther (2014) 0.75
Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. Mol Cancer Ther (2002) 0.75
Erratum: Achilles' heel of triple negative cancer. Oncoscience (2014) 0.75
β-Lapachone analogs with enhanced antiproliferative activity. Eur J Med Chem (2012) 0.75